# 2025 DEBATES AND DIDACTICS in Hematology and Oncology



Where Science Becomes Hope

#### JULY 24 - 27, 2025 · SEA ISLAND, GEORGIA

This activity is jointly provided by

CELEBRATING

FARS of DDHO





## **Best Neoadjuvant Option for Melanoma**

Michael Lowe, MD, MA, FACS, FSSO **Associate Professor Emory University School of Medicine** 







# Best Neoadjuvant Option for Melanoma Pembrolizumab

Michael Lowe, MD, MA, FACS, FSSO Associate Professor Emory University School of Medicine






#### **Disclosures**

• Consultant to and research funding from both Merck and BMS

#### Background


SW0G1801

NADINA




Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708. .

#### Background – S1801 design




Patel, et al. NEJM. 2023:388;813-823.


#### **Background – NADINA design**



Blank, et al. NEJM. 2024:391:1696-1708.



Patel, et al. NEJM. 2023:388;813-823.




#### NADINA

Blank, et al. NEJM. 2024:391:1696-1708.

Trial	Rate of MPR (central)
SW0G-S1801	53%
NADINA	59%

Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708.



Menzies, et al. Nature Medicine. 2021; 27:301-309.

#### Reasons to Give Nivo/Ipi: Higher event-free survival rate

Trial	1-year EFS (neoadj arm)	2-year EFS (neoadj arm)
SW0G-S1801	72%	72%
NADINA	84%	N/A

Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708.

#### Reasons to Give Nivo/Ipi: Higher recurrence-free survival rate

Trial	1-year RFS for MPR
SW0G-S1801	91%
NADINA	95%

Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708.


#### Reasons to Give Nivo/Ipi: Higher recurrence-free survival rate

Trial	1-year RFS for MPR	1-year RFS for pPR	1-year RFS for pNR
SW0G-S1801	91%	93%	76%
NADINA	95%	76%	57%

Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708.


#### Reasons to Give Nivo/Ipi: Avoid adjuvant therapy for MPR

#### **Reminder – NADINA design**



Blank, et al. NEJM. 2024:391:1696-1708.


### Reasons to Give Nivo/Ipi: Avoid adjuvant therapy for MPR



Blank, et al. NEJM. 2024:391:1696-1708.

### Reasons to Give Nivo/Ipi: Avoid adjuvant therapy for MPR

Keynote 716: Adjuvant pembrolizumab for high-risk stage II melanoma



Luek, et al. Lancet. 2022:399; 1718-1729.

#### **Reasons to Give Pembro: Lower toxicity**

- SWOG1801
  - Treatment-related grade 3/4 toxicity: 12.0%
- NADINA



• Treatment-related grade 3/4 toxicity: 29.7%

Event	Neoadjuvant Group (N=212)
Any adverse event — no. (%)	204 (96.2)

Patel, et al. NEJM. 2023:388;813-823. Blank, et al. NEJM. 2024:391:1696-1708.

### **Best Neoadjuvant Option for Melanoma: Pembrolizumab**

- Near equivalent pathologic response rate
  - No clear connection between response rate and survival
- Near equivalent event-free survival rate
  - When accounting for differences in definitions of EFS
- Near equivalent recurrence-free survival rate
  - Superior RFS for non-responders
- No randomized data proving its safe to forego adjuvant therapy for major pathologic responders
- 2.5 times lower rate of toxicity

### Good Luck, Melinda...

Yours Truly,

Michael Lowe, MD, MA, FACS, FSSO Associate Professor Emory University School of Medicine

